GlassScriptPhysician profile
Rachel Shu
NPI 1942358577
$3,754.45
in general payments reported to CMS, 2019-2025
26 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $858 · 2021: $619 · 2022: $531 · 2023: $258 · 2024: $362 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.40 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $620.06 | 2019-2022 | |
| Amgen INC. | $585.64 | 2019-2023 | Prolia, Evenity |
| Therapeuticsmd, INC. | $451.27 | 2019-2022 | |
| Ethicon US, LLC | $248.03 | 2021-2024 | Harmonic, Stratafix, Dermabond |
| Janssen Pharmaceuticals, INC | $200.87 | 2019-2024 | Xarelto |
| Avion Pharmaceuticals | $177.66 | 2019-2021 | |
| Astellas Pharma US INC | $165.58 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $145.33 | 2019-2022 | |
| Sage Therapeutics, LLC | $122.47 | 2019 | |
| Merck Sharp & Dohme LLC | $120.19 | 2019 | |
| Myovant Sciences INC. | $119.98 | 2021-2022 | |
| Medical Device Business Services, INC. | $111.00 | 2024 | Vistaseal |
| Aspira Women'S Health INC | $110.01 | 2019 | |
| Applied Medical Resources Corporation | $105.61 | 2020 | |
| Mylan Pharmaceuticals INC. | $97.04 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $68.20 | 2021-2022 | |
| Coopersurgical, INC. | $64.89 | 2020-2023 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $56.55 | 2025 | |
| Exeltis, USA INC. | $32.84 | 2019 | |
| Roche Diagnostics Corporation | $28.83 | 2021 | |
| Sumitomo Pharma America, INC. | $24.42 | 2025 | Myfembree |
| Hologic Sales and Service, LLC | $23.43 | 2022 | |
| Amag Pharmaceuticals, INC. | $22.67 | 2020 | |
| Organon LLC | $17.87 | 2021 | |
| Minerva Surgical, INC | $17.09 | 2024 | |
| Biogen, INC. | $16.92 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Shu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.